Bryan D. Beel

Senior Counsel

Portland

Print bio

503.727.2116 direct

BBeel@perkinscoie.com

Notice

Before proceeding, please note: If you are not a current client of Perkins Coie, please do not include any information in this e-mail that you or someone else considers to be of a confidential or secret nature. Perkins Coie has no duty to keep confidential any of the information you provide. Neither the transmission nor receipt of your information is considered a request for legal advice, securing or retaining a lawyer. An attorney-client relationship with Perkins Coie or any lawyer at Perkins Coie is not established until and unless Perkins Coie agrees to such a relationship as memorialized in a separate writing.

vCard

Bryan works with company clients on patent litigation matters, focusing on representing pharmaceutical companies in Hatch-Waxman litigation.

Dr. Bryan Beel is an experienced litigator, focused on patent litigation in district court and inter partes review proceedings. He also counsels clients on patent and trademark prosecution issues, offering guidance on the most effective and favorable ways to resolve a dispute.

Bryan's advanced training lies in the areas of biotechnology, molecular biology, biochemistry, protein structure modifications, and analysis of the dynamics of signaling systems. Bryan regularly defends some of the world's largest pharmaceutical manufacturers in patent litigation involving drug substances, product formulations, and methods of treating diseases and disorders. Bryan extends this work beyond federal district court litigation and has experience challenging pharmaceutical patents in inter partes review proceedings at the U.S. Patent and Trademark Office, including one of the first successful proceedings in this area.

Bryan is a founding editor and writer for Life Science Legal Report, the firm's blog focused on patent decisions and developments affecting the life sciences industry.

Areas of focus

Industries

Biotechnology & Pharmaceutical

Digital Media & Entertainment, Gaming & Sports

Interactive Entertainment

Medical Device

Life Sciences & Healthcare

Services

Litigation

Patent Litigation

Intellectual Property Law

Patent Prosecution & Portfolio Counseling

Education & Credentials

Education

Lewis & Clark Law School, J.D., Assistant Editor, Oregon Intellectual Property Newsletter, 2007
Washington State University, Ph.D., Genetics and Cell Biology, 1999
St. John's University, B.A., Natural Science, 1992

Bar and Court Admissions

Oregon

U.S. Court of Appeals for the Federal Circuit
U.S. Court of Appeals for the Fourth Circuit
U.S. Court of Appeals for the Ninth Circuit
U.S. District Court for the District of Oregon

Related Employment

Perkins Coie LLC, Portland, OR, Contract Review Center/Litigation Attorney, 2009-2010
Kolisch Hartwell, P.C., Portland, OR, Technical Consultant, 2004-2007; Intellectual Property Attorney, 2007-2009
California Institute of Technology, Pasadena, CA, Postdoctoral Scholar, Division of Biology, 2000-2004

Professional Recognition

Listed in Super Lawyers Magazine as an "Oregon Rising Star," 2013-2017; "Oregon Super Lawyer," 2018-2024

Impact

Professional Leadership

City of Camas, City Planning Commission, Chairman
Oregon Bioscience Association, Government Relations Committee, 2013-present
Oregon State Bar, Chairman of the Federal Practice and Procedure Committee
American Bar Association, Sections of Litigation and Intellectual Property
Federal Bar Association, Member; Board of Directors, 2013-2018
American Intellectual Property Law Association
Multnomah County Bar Association
U.S. District Court for the District of Oregon Pro Bono Panel
Ninth Circuit Court of Appeals Pro Bono Representation Panel
Oregon State Bar Volunteer Disciplinary Defense Counsel

Community Involvement

Washington Timbers Football Club, Director/Board of Directors

Professional Experience

Patent Litigation

Novartis Pharmaceuticals Corporation v. Dr. Reddy’s Laboratories, Inc.

U.S. District Court for the District of Delaware
Representing Dr. Reddy’s Laboratories in Hatch-Waxman litigation in the District of Delaware, contesting the validity and infringement of patents relating to sacubitril/valsartan (Entresto®). Case is ongoing.

Viiv Healthcare Co. v. Mylan Pharmaceuticals Inc.

U.S. District Court for the District of Delaware
U.S. District Court for the Northern District of West Virginia
Representing Mylan in the District of Delaware and the Northern District of West Virginia in Hatch-Waxman litigation over patent rights to abacavir sulfate/dolutegravir/lamivudine (Triumeq®). Case is ongoing.

Novartis Pharmaceuticals Corp. et al. v. Mylan Pharmaceuticals Inc.

Mylan Pharmaceuticals Inc. v. Janssen Oncology, Inc.

U.S. Patent and Trademark Office
Representing Mylan in inter partes review before the United States Patent and Trademark Office, challenging patent claims related to abiraterone acetate (Zytiga®). The case is pending before the Patent Trial and Appeal Board.

Janssen Biotech, Inc. v. Mylan Inc.

U.S. District Court for the District of New Jersey
U.S. District Court for the Northern District of West Virginia
Representing Mylan in the District of New Jersey and the Northern District of West Virginia in Hatch-Waxman litigation over patent rights to abiraterone acetate (Zytiga®). Case is ongoing.

Mylan Pharmaceuticals Inc. v. Novartis AG

U.S. Patent and Trademark Office
Representing Mylan in inter partes review before the United States Patent and Trademark Office, challenging patent claims related to fingolimod (Gilenya®). The Patent Trial and Appeal Board cancelled the challenged claims, and the Federal Circuit affirmed the PTAB’s ruling, on appeal.

InterMetro Industries Corporation v. Capsa Solutions, LLC

U.S. District Court for the Middle District of Pennsylvania
Represented Capsa in litigation in the Middle District of Pennsylvania over patent rights to mobile computer workstations used in the medical field. Negotiated a successful settlement agreement allowing Capsa to market its workstation products.

Horizon Pharmaceuticals, et al. v. Mylan Pharmaceuticals Inc., et al.

U.S. Court of Appeals for the Federal Circuit
U.S. District Court for the District of New Jersey
Represented Mylan in three Hatch-Waxman litigations in the District of New Jersey and the Federal Circuit Court of Appeals over patent rights to naproxen/esomeprazole magnesium tablets (Vimovo®), used to treat the risk of ulcer formation in patients requiring long-term treatment with non-steroidal anti-inflammatory drugs. After Mylan successfully obtained judgments of invalidity of four patents, a settlement agreement was reached.

AstraZeneca AB, et al. v. Mylan Laboratories Ltd., et al.

U.S. District Court for the District of New Jersey
Representing Mylan in Hatch-Waxman litigation over patent rights to esomeprazole (Nexium®). Defeated motion for a preliminary injunction in the district court, allowing Mylan to market a generic esomeprazole (Nexium®) product. Negotiated a successful settlement agreement allowing Mylan to market its generic Nexium® product.

The Arizona Board Of Regents for and on behalf of Arizona State University v. Seattle Genetics, Inc.

U.S. District Court for the District of Arizona
Represented Arizona State University in litigation in the District of Arizona over patent rights to cancer drug.

Teva Pharmaceuticals USA Inc. et al. v. Mylan Pharmaceuticals Inc. et al.

U.S. Supreme Court
U.S. Court of Appeals for the Federal Circuit
U.S. District Court for the Southern District of New York
Represent and advise Mylan in various suits venued domestically (e.g., the Southern District of New York, Federal Circuit, and United States Supreme Court) and abroad related to alleged infringement of patents on a copolymer of amino acids for the treatment of multiple sclerosis (Copaxone®). In the domestic case, a decision by the United States Supreme Court resulted in a favorable invalidity ruling by the Federal Circuit. International litigation is ongoing.

Pfizer Inc. et al. v. Mylan Inc. et al.

U.S. District Court for the District of Delaware
Represented Mylan in Hatch-Waxman litigation over patent rights to atorvastatin calcium (Lipitor®). Negotiated a successful settlement agreement allowing Mylan to market its generic Lipitor® product.

Medicis Pharmaceutical Corporation v. Mylan Inc. et al.

U.S. District Court for the District of Delaware
Represented Mylan in Hatch-Waxman litigation over patent rights to the acne medication minocycline hydrochloride extended release tablets (Solodyn®). Negotiated a favorable settlement agreement allowing Mylan to market its generic minocycline product.

Birchwood Laboratories Inc. v. Battenfeld Technologies Inc. / Battenfeld Technologies Inc. v. Birchwood Laboratories Inc.

U.S. District Court for the District of Minnesota
Won a series of summary judgments for Battenfeld on issues of obviousness, inequitable conduct, enablement, best mode, indefiniteness and willful infringement in patent infringement case involving sport shooting targets.

Google Inc. v. Traffic Information, LLC

U.S. District Court for the District of Oregon
Represented Google Inc. in a declaratory judgment patent action relating to traffic information provided to mapping applications.

Jugs Sports v. World Sports Products / World Sports Products v. The Jugs Company*

U.S. District Court for the District of Utah
Represented sporting goods manufacturer in patent litigation related to patents claiming baseball- and ball-throwing machines.

Contested Patent Matters

Mylan Pharmaceuticals Inc. v. Horizon Pharma, Inc. and Pozen Inc.

Patent Trial and Appeal Board
Representing Mylan in inter partes review challenging U.S. Patent No. 9,220,698, with claims related to naproxen/esomeprazole magnesium tablets (Vimovo®). The case is pending before the Patent Trial and Appeal Board.

Mylan Pharmaceuticals Inc. v. Horizon Pharma, Inc. and Pozen Inc.

Patent Trial and Appeal Board
Representing Mylan in inter partes review challenging U.S. Patent No. 9,393,208, with claims related to naproxen/esomeprazole magnesium tablets (Vimovo®). The case is pending before the Patent Trial and Appeal Board.

Mylan Pharmaceuticals Inc. v. Janssen Oncology, Inc.

Patent Trial and Appeal Board
Representing Mylan in inter partes review challenging U.S. Patent No. 8,822,438, with claims related to abiraterone acetate (Zytiga®). The PTAB held all claims unpatentable. The case is pending a rehearing request before the Patent Trial and Appeal Board.

Mylan Pharmaceuticals Inc. v. Novartis AG

Patent Trial and Appeal Board
Represented Mylan in inter partes review challenging U.S. Patent No. 8,324,283, with claims related to fingolimod (Gilenya®). The Patent Trial and Appeal Board cancelled the challenged claims, and the Federal Circuit affirmed the PTAB’s ruling, on appeal.

Litigation

Hospira, Inc. et al. v. Sylvia Matthews Burwell, et al.

U.S. Court of Appeals for the Fourth Circuit
U.S. District Court for the District of Maryland
Represented intervenor-defendant Mylan Institutional LLC in a suit brought by Hospira in the District of Maryland against the U.S. Food and Drug Administration to rescind approval of a generic sedative. Successfully obtained summary judgment, allowing Mylan to market its product. After Hospira appealed to Fourth Circuit, negotiated a successful settlement agreement.

Furlong v. Pure Grace, Inc.*

U.S. District Court for the District of Oregon
Represented designer in trademark, copyright, and trade secret litigation related to porcelain ornaments and processes for manufacturing them.

*Prior firm experience